Population Pharmacokinetics of Vancomycin in Pregnant Women

Objective: Vancomycin is a glycopeptide antibacterial indicated for serious gram-positive infections. Pharmacokinetics (PK) of vancomycin have not been described in pregnant women. This study aims to characterize the PK disposition of vancomycin in pregnant women based on data acquired from a databa...

Full description

Bibliographic Details
Main Authors: Rahul K. Goyal, Brady S. Moffett, Jogarao V. S. Gobburu, Mayar Al Mohajer
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.873439/full
_version_ 1818535581871767552
author Rahul K. Goyal
Brady S. Moffett
Brady S. Moffett
Jogarao V. S. Gobburu
Mayar Al Mohajer
author_facet Rahul K. Goyal
Brady S. Moffett
Brady S. Moffett
Jogarao V. S. Gobburu
Mayar Al Mohajer
author_sort Rahul K. Goyal
collection DOAJ
description Objective: Vancomycin is a glycopeptide antibacterial indicated for serious gram-positive infections. Pharmacokinetics (PK) of vancomycin have not been described in pregnant women. This study aims to characterize the PK disposition of vancomycin in pregnant women based on data acquired from a database of routine hospital care for therapeutic drug monitoring to better inform dosing decisions.Methods: In this study, plasma drug concentration data from 34 pregnant hospitalized women who were administered intravenous vancomycin was analyzed. A population pharmacokinetic (PPK) model was developed using non-linear mixed effects modeling. Model selection was based on statistical criterion, graphical analysis, and physiologic relevance. Using the final model AUC0-24 (PK efficacy index of vancomycin) was compared with non-pregnant population.Results: Vancomycin PK in pregnant women were best described by a two-compartment model with first-order elimination and the following parameters: clearance (inter individual variability) of 7.64 L/hr (32%), central volume of 67.35 L, inter-compartmental clearance of 9.06 L/h, and peripheral volume of 37.5 L in a typical patient with 175 ml/min creatinine clearance (CRCL) and 45 kg fat-free mass (FFM). The calculated geometric mean of AUC0-24 for the pregnant population was 223 ug.h/ ml and 226 ug.h/ ml for the non-pregnant population.Conclusion: Our analysis suggests that vancomycin PK in pregnant women is consistent with non-pregnant adults and the dosing regimens used for non-pregnant patients may also be applicable to pregnant patients.
first_indexed 2024-12-11T18:26:49Z
format Article
id doaj.art-73fd39602953431b8bfedfbf8501c300
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-11T18:26:49Z
publishDate 2022-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-73fd39602953431b8bfedfbf8501c3002022-12-22T00:55:02ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-06-011310.3389/fphar.2022.873439873439Population Pharmacokinetics of Vancomycin in Pregnant WomenRahul K. Goyal0Brady S. Moffett1Brady S. Moffett2Jogarao V. S. Gobburu3Mayar Al Mohajer4University of Maryland, Baltimore, MD, United StatesTexas Children’s Hospital, Houston, TX, United StatesBaylor College of Medicine, Houston, TX, United StatesUniversity of Maryland, Baltimore, MD, United StatesBaylor College of Medicine, Houston, TX, United StatesObjective: Vancomycin is a glycopeptide antibacterial indicated for serious gram-positive infections. Pharmacokinetics (PK) of vancomycin have not been described in pregnant women. This study aims to characterize the PK disposition of vancomycin in pregnant women based on data acquired from a database of routine hospital care for therapeutic drug monitoring to better inform dosing decisions.Methods: In this study, plasma drug concentration data from 34 pregnant hospitalized women who were administered intravenous vancomycin was analyzed. A population pharmacokinetic (PPK) model was developed using non-linear mixed effects modeling. Model selection was based on statistical criterion, graphical analysis, and physiologic relevance. Using the final model AUC0-24 (PK efficacy index of vancomycin) was compared with non-pregnant population.Results: Vancomycin PK in pregnant women were best described by a two-compartment model with first-order elimination and the following parameters: clearance (inter individual variability) of 7.64 L/hr (32%), central volume of 67.35 L, inter-compartmental clearance of 9.06 L/h, and peripheral volume of 37.5 L in a typical patient with 175 ml/min creatinine clearance (CRCL) and 45 kg fat-free mass (FFM). The calculated geometric mean of AUC0-24 for the pregnant population was 223 ug.h/ ml and 226 ug.h/ ml for the non-pregnant population.Conclusion: Our analysis suggests that vancomycin PK in pregnant women is consistent with non-pregnant adults and the dosing regimens used for non-pregnant patients may also be applicable to pregnant patients.https://www.frontiersin.org/articles/10.3389/fphar.2022.873439/fullvancomycinpregnancytherapeutic drug monitoringpopulation pharmacokinetic (PK) modelobstericsantibiotics
spellingShingle Rahul K. Goyal
Brady S. Moffett
Brady S. Moffett
Jogarao V. S. Gobburu
Mayar Al Mohajer
Population Pharmacokinetics of Vancomycin in Pregnant Women
Frontiers in Pharmacology
vancomycin
pregnancy
therapeutic drug monitoring
population pharmacokinetic (PK) model
obsterics
antibiotics
title Population Pharmacokinetics of Vancomycin in Pregnant Women
title_full Population Pharmacokinetics of Vancomycin in Pregnant Women
title_fullStr Population Pharmacokinetics of Vancomycin in Pregnant Women
title_full_unstemmed Population Pharmacokinetics of Vancomycin in Pregnant Women
title_short Population Pharmacokinetics of Vancomycin in Pregnant Women
title_sort population pharmacokinetics of vancomycin in pregnant women
topic vancomycin
pregnancy
therapeutic drug monitoring
population pharmacokinetic (PK) model
obsterics
antibiotics
url https://www.frontiersin.org/articles/10.3389/fphar.2022.873439/full
work_keys_str_mv AT rahulkgoyal populationpharmacokineticsofvancomycininpregnantwomen
AT bradysmoffett populationpharmacokineticsofvancomycininpregnantwomen
AT bradysmoffett populationpharmacokineticsofvancomycininpregnantwomen
AT jogaraovsgobburu populationpharmacokineticsofvancomycininpregnantwomen
AT mayaralmohajer populationpharmacokineticsofvancomycininpregnantwomen